### Wachtell, Lipton, Rosen & Katz

MARTIN LIPTON
LEBRERET M. WACHTELL
BERNARD W. NUSSBALIM
LEBRINARD W. NUSSBALIM
AWIENCE B. PEDOWITZ
AMUL VIZ CARRONDO, IR.
ALI VIZ CARRONDO, IR.
BENCH W. LEBRING W. LEBRING
LEBRING W. LEBRING

STEPHANIE J. SELIGMAN
JOHN F. SWIRKES
JOHN F.

51 WEST 52ND STREET NEW YORK, N.Y. 10019-6150 TELEPHONE: (212) 403 -1000 FACSIMILE: (212) 403 -2000

> GEORGE A. KATZ (1965-1989) JAMES H. FOGELSON (1967-1991)

> > OF COUNSEL

WILLIAM T. ALLEN
PETER C. CANELLOS
DAVID M. EINHORN
THEODORE GEWERTZ
RICHARD D. KATCHER
THEODORE A. LEVINE
DOUGLAS K. MAYER
ROBERT B. MAZUR
PHILIP MINDLIN
ROBERT M. MORGENTE

ERIC S. ROBINSON
PATRICIA A. ROBINSON
LEONARD M. ROSEN
MICHAEL W. SCHWART:
ELLIOTT V. STEIN
WARREN R. STERN
WARREN R. STERN
PATRICIA A. VLAHAKIS
J. BRYAN WHITWORTH
AMY R. WOLF

\* ADMITTED IN THE DISTRICT OF COLUMBIA

COUNSEL

DAVID M. ADLERSTEIN MICHELE J. ALEXANDER LOUIS J. BARASH DIANNA CHEN ANDREW J.H. CHEUNG PAMELA EHRENKRANZ PAULA N. GORDON NANCY B. GREENBAUM MAURA R. GROSSMAN MARK A. KOENIG J. AUSTIN LYONS AMANDA N. PERSAUD JEFFREY A. WATIKER

Direct Fax: (212) 403-2394 E-Mail: DKLam@wlrk.com November 30, 2012 DAWID C. BEYAN STEVEN A. COHEN DEBORAH I. PAUL DAWID C. KAPP RICHARD K. KIM DOSEHD A. CAMMAKER JOSEHD D. LARSON WEANNEAMARE O'BRIEN WAYNE M. CARLIN MAYNEM C. ARLIN M. COFFERD DE MANDEN MICHOLAS G. DEMMO GOR KIRMAN JONATHAN M. MOSES LE RICO STANCE JONATHAN M. MOSES MARTIN J.E. ARMS
GREGORY E. OSTLING
DAVID B. ANDERS
ADAM J. SHAPIRO
NELSON O. FITTS
USERMY L. GOLDSTEIN
JOSHUA M. HOLMES
DAVID E. SHAPIRO
DAMIAN G. DIDDEN
ANTE VUCIC
IAN BOCZKO
MATTHEW M. GUEST
DAVID E. KAHAN
DAVID K. LARIAN
DOSHUA A. FELTMAN
ELAINE F. GOLIN
EMIL A. KLEISHAUS

# **VIA HAND DELIVERY AND EDGAR**

Mr. Jeffrey P. Riedler Assistant Director Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549

Re: AbbVie Inc.

Amendment No. 5 to Registration Statement on Form 10-12B

Filed November 16, 2012 File No. 001-35565

Dear Mr. Riedler:

On behalf of our client, AbbVie Inc. (the "<u>Company</u>"), which is currently a wholly owned subsidiary of Abbott Laboratories ("<u>Abbott</u>"), we are providing the Company's responses to the comments of the Staff of the Division of Corporation Finance (the "<u>Staff</u>") of the U.S. Securities and Exchange Commission (the "<u>Commission</u>") set forth in your letter, dated November 27, 2012, with respect to the filing referenced above.

This letter and Amendment No.6 ("<u>Amendment No. 6</u>") to the Registration Statement on Form 10 (File No. 001-35565) (the "<u>Registration Statement</u>" or the "<u>Form 10</u>") are being filed electronically via the EDGAR system today. In addition to the EDGAR filing, we are delivering a hard copy of this letter, along with six copies of Amendment No. 6 marked to

WACHTELL, LIPTON, ROSEN & KATZ Mr. Jeffrey P. Riedler U.S. Securities and Exchange Commission November 30, 2012 Page 2

indicate changes from the version of the Registration Statement filed on November 16, 2012 ("Amendment No. 5").

For the Staff's convenience, the text of the Staff's comments is set forth below in bold, followed in each case by the Company's response. Terms not otherwise defined in this letter shall have the meanings set forth in Amendment No. 6. All references to page numbers in these responses are to the pages of the information statement filed as Exhibit 99.1 to Amendment No. 6 (the "Information Statement").

## General

1. Please file as an exhibit the purchase agreement entered into on November 5, 2012 by and among yourself, Abbott Laboratories and the representatives of the initial purchasers of your convertible notes.

<u>Response</u>: The exhibit list to the Registration Statement has been revised in response to the Staff's comment to include the executed purchase agreement between the Company, Abbott Laboratories, as guarantor, and the representatives of the initial purchasers of the Company's senior notes. The Company has filed a complete copy of the agreement as Exhibit 10.21 to the Registration Statement.

## Unaudited pro forma condensed combined balance sheet, page 42

2. Please revise to include a cross reference to a footnote for the \$1,000 short-term debt pro forma adjustment. If you do not include disclosure of the short-term debt in footnote G, please revise footnote G to disclose the amount of long-term debt as \$14.7 billion.

*Response*: The Information Statement has been revised on pages 43–44 in response to the Staff's comment.

\* \* \*

If you have any questions, please do not hesitate to contact the undersigned at (212) 403-1394 or Karessa L. Cain at (212) 403-1128.

Very truly yours,

/s/ David K. Lam

David K. Lam

#### **Enclosures**

cc: Richard A. Gonzalez, Chairman of the Board and Chief Executive Officer (AbbVie Inc.) Laura J. Schumacher, EVP, General Counsel and Secretary (Abbott Laboratories)